Divi's Laboratories reported a consolidated profit after tax (PAT) of ₹583 crore, marginally lower than ₹589 crore in the same period last year ...

Jefferies appeared the most bullish on the counter, hiking the target price, while Morgan Stanley reduced the target price, ...

Management said operational metrics improved during the quarter despite near-term revenue softness and indicated that growth ...

Divi's Laboratories reported Q3FY26 results with a PAT of ₹583 crore, slightly down from ₹589 crore year-over-year. Total ...

Feb 11 (Reuters) - Indian contract drug manufacturer Divi's Laboratories reported third-quarter profit below estimates on Wednesday, as high raw material costs and a one-off charge due to changes in ...

Analysts have tweaked share price targets and future outlook after some of these companies announced their December quarter ...

Nifty IT plunges 12%, raising downtrend fears as attention shifts to Divi's Lab, Apollo Hospitals, and 7 key stocks; check the latest market outlook!

Earnings call Divi's Laboratories reported Q3 FY26 revenue of ₹2,692 Cr, up 12.1% YoY, with profit before tax (ex-exceptional) rising 17.6% YoY to ₹854 Cr. Gross margin improved significantly due to ...

This article first appeared on GuruFocus. Divi's Laboratories Ltd (NSE:DIVISLAB) is set to release its Q3 2026 earnings on Feb 11, 2026. The consensus estimate for Q3 2026 revenue is $25.96 billion, ...

Net profit for the December quarter fell 1 percent year‑on‑year to Rs.583 crore, compared with Rs.589 crore a year earlier, weighed down by a Rs.74‑crore exceptional charge arising from India’s newly ...

Divi's Labs reported a weaker-than-expected set of headline numbers on Wednesday.